BCMA-targeted chimeric antigen receptor (CAR) T cells induce high objective response rates (ORRs) in patients with relapsed or refractory multiple myeloma (MM), but most will eventually have disease progression. Now, data from a phase I trial show that CAR T cells targeting a different plasma cell antigen, GPRC5D, are active in this setting.